Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
BELGRADE, Mont., Feb. 03, 2016 -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), formerly Bacterin International Holdings, Inc., a leader in the development of class-leading regenerative medicine products and medical devices, today announced that its Chief Executive Officer, Dan Goldberger and Chief Financial Officer, John Gandolfo will present at the inaugural Source Capital 2016 Disruptive Growth & Healthcare Conference, to be held February 10-11, 2016 at the Convene Conference Center in New York City, NY. Xtant Medical's presentation will take place Wednesday, February 10, 2016 at 10:15 AM Eastern Time.
A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Info" section of the Company's website at www.xtantmedical.com. A replay of the conference presentation will also be available.
About Xtant Medical Holdings
Xtant Medical Holdings, Inc. (NYSE MKT:XTNT) develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. With core competencies in both biologic and non-biologic surgical technologies, Xtant can leverage its resources to successfully compete in global neurological and orthopedic surgery markets. For further information, please visit www.xtantmedical.com.
Important Cautions Regarding Forward-looking Statements
This press release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to successfully integrate the acquisition of X-spine; the ability of the Company's sales force to achieve expected results, the Company's ability to meet its existing and anticipated contractual obligations, including financial covenant and other obligations contained in the Company's secured lending facility; the Company's ability to manage cash flow; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's customers to pay and the timeliness of such payments; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
Contact: COCKRELL GROUP 877.889.1972 [email protected] cockrellgroup.com
